Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy.

Simon J HongCameron ZengerJillian PecorielloAlice PangMargaret VallelyDavid P HudesmanShannon ChangJordan E Axelrad

Published in: Inflammatory bowel diseases (2022)

Exposure to ustekinumab or vedolizumab in patients with IBD and a prior history of cancer does not appear to be associated with an increased risk of subsequent new or recurrent cancer.

Keyphrases

papillary thyroid
ulcerative colitis
young adults